Eris Lifesciences to Acquire Remaining 30% Shares of Swiss Parenterals for INR 423 Crores

Eris Lifesciences Ltd. has announced its decision to acquire the remaining 30% shares of its subsidiary, Swiss Parenterals Limited, from Mr. Naishadh Shah for a total purchase consideration of INR 423,30,00,000. The acquisition will be discharged by the issuance of up to 23,06,372 equity shares of the Company on a preferential basis to Mr. Naishadh Shah. Swiss Parenterals Limited is a pharmaceuticals company incorporated in 1997, with a history of increasing turnover and a presence in over 80 countries. The acquisition is expected to complete prior to March 31, 2026.